Akebia Therapeutics vs Valneva
Akebia Therapeutics is the larger business, with $236m of revenue in fiscal 2025 against $197m for Valneva (1.2 times as much). Akebia Therapeutics grew faster (47.5% against 7.6%). Akebia Therapeutics kept more of each dollar of sales as profit: a net margin of -2.3% against -66.0%.
| Latest fiscal year | Akebia TherapeuticsAKBA, 2025 | ValnevaVALN, 2025 |
|---|---|---|
| Revenue | $236m | $197m |
| Revenue growth | 47.5% | 7.6% |
| Net income | −$5.3m | −$130m |
| Operating margin | — | -47.0% |
| Net margin | -2.3% | -66.0% |
| Return on equity | — | -83.4% |
| Free cash flow | $67.7m | −$64.8m |
| Cash | $185m | $129m |
| Total debt | $52.4m | $210m |
| Debt to equity | — | 168.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 194 | — |
| Market value | $193m | $476m |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | — |
| Insider trades, 12 months | 1 buys, 16 sales | 0 buys, 0 sales |